Park-Wyllie LY - Search Results

1

Adverse quality of life consequences of antiretroviral medications.

Park-Wyllie LY, Strike CS, Antoniou T, Bayoumi AM. Park-Wyllie LY, et al. AIDS Care. 2007 Feb;19(2):252-7. doi: 10.1080/09540120600774180. AIDS Care. 2007. PMID: 17364407

2

Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS.

Rueda S, Park-Wyllie LY, Bayoumi AM, Tynan AM, Antoniou TA, Rourke SB, Glazier RH. Rueda S, et al. Among authors: park wyllie ly. Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD001442. doi: 10.1002/14651858.CD001442.pub2. Cochrane Database Syst Rev. 2006. PMID: 16855968 Free PMC article. Review.

3

Outcomes of dosage adjustments used to manage antiretroviral drug interactions.

Park-Wyllie LY, Levine MA, Holbrook A, Thabane L, Antoniou T, Yoong D, Kam D, Bayoumi AM. Park-Wyllie LY, et al. Clin Infect Dis. 2007 Oct 1;45(7):933-6. doi: 10.1086/521252. Epub 2007 Aug 20. Clin Infect Dis. 2007. PMID: 17806064

4

The adherence support gap: the 'ideal' versus 'reality' of antiretroviral adherence support provided by HIV health providers in clinical practice.

Park-Wyllie LY, Kam D, Bayoumi AM. Park-Wyllie LY, et al. Ann Pharmacother. 2009 Jun;43(6):1036-44. doi: 10.1345/aph.1L663. Epub 2009 Jun 2. Ann Pharmacother. 2009. PMID: 19491319

5

Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.

Antoniou T, Park-Wyllie LY, Tseng AL. Antoniou T, et al. Pharmacotherapy. 2003 Jan;23(1):29-43. doi: 10.1592/phco.23.1.29.31915. Pharmacotherapy. 2003. PMID: 12523458 Review.

6

Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series.

Park-Wyllie LY, Antoniou T. Park-Wyllie LY, et al. AIDS. 2003 Mar 7;17(4):638-40. doi: 10.1097/00002030-200303070-00025. AIDS. 2003. PMID: 12598790 No abstract available.

7

Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphoma.

Cheung MC, Imrie KR, Leitch HA, Park-Wyllie LY, Buckstein R, Antoniou T, Loutfy MR. Cheung MC, et al. Among authors: park wyllie ly. Ann Hematol. 2007 Sep;86(9):631-8. doi: 10.1007/s00277-007-0284-8. Epub 2007 Mar 20. Ann Hematol. 2007. PMID: 17372734

8

A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy.

Antoniou T, Park-Wyllie L, Boyle E. Antoniou T, et al. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1666-7. doi: 10.1097/00126334-200412150-00023. J Acquir Immune Defic Syndr. 2004. PMID: 15577427 Clinical Trial. No abstract available.

9

Challenges of adherence management in human immunodeficiency virus pharmacotherapy.

Park-Wyllie LY, Phillips EJ. Park-Wyllie LY, et al. Can J Clin Pharmacol. 2003 Winter;10(4):189-95. Can J Clin Pharmacol. 2003. PMID: 14712324 Review.

10

High rate of discontinuations of highly active antiretroviral therapy as a result of antiretroviral intolerance in clinical practice: missed opportunities for adherence support?

Park-Wyllie LY, Scalera A, Tseng A, Rourke S. Park-Wyllie LY, et al. AIDS. 2002 May 3;16(7):1084-6. doi: 10.1097/00002030-200205030-00021. AIDS. 2002. PMID: 11953481 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters